Clinical trial
The Prognostic Role of the Lactate/Albumin Ratio in Predicting 28-Day Mortality in Patients Admitted to the Intensive Care Unit With a Diagnosis of Respiratory Failure
NCT07909226 is registered in ClinicalTrials.gov with Kocaeli City Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Prognostic Role of the Lactate/Albumin Ratio in Predicting 28-Day Mortality in Patients Admitted to the Intensive Care Unit With a Diagnosis of Respiratory Failure
- Lead sponsor
- Kocaeli City Hospital
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- November 1, 2026
- Completion date
- March 1, 2027
- Enrollment
- 1,250 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute respiratory failure, critical illness, mortality, mortality prediction
Lead sponsor's other trials
Kocaeli City Hospital, most recent start first.
+38 more trials See the organization page
Similar trials
Same condition (Critical Illness) and phase, most recent start first.
+822 more trials See the condition page